Mounjaro has been on the FDA's shortage list since late 2022, while Zepbound was added to the list in April this year.

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and ...

The latest investment in the Lebanon site comes after an announcement in May of $5.3 billion earmarked to build production ...

Eli Lilly & Co. is pouring $4.5 billion into a new manufacturing plant in Indiana to make drugs for future clinical trials, ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The shortage of all doses of the drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management has been ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when ...